PDP1 and acute myeloid leukemia: FLT3-ITD-associated PDP1 overexpression stimulates OXPHOS, a metabolic pathway that mediates AML resistance against cytotoxic events like chemotherapy such as Ara-C, or tyrosine kinase inhibitor (TKI) treatment [25, 70–72].